Do i need to say more about the future of the company. Outlook...

Do i need to say more about the future of the company.
Outlook In FY20, the Company expects stronger results driven by the recent specialty brand launches of TOLSURA and LEXETTE, growth of the generic and proprietary dermatology and women’s health portfolios and accelerated growth of Metrics Contract Services driven by additional headcount, the expanded manufacturing and testing footprint in Greenville and delivery of the pipeline of committed business. The Company is targeting eight new product launches by the end of CY20 of which two are already approved and three have no generic equivalents today. In addition, various initiatives at the Company’s manufacturing sites in Greenville and Salisbury are expected to drive greater operational efficiencies and improved financial performance across FY20 and beyond. The Company also expects to further optimise its cost base through reducing operating expenses via more controlled spending and realising significant cost savings from product transfers in house or to new contract manufacturers.